| P50 | author | Nicolás Saavedra | Q82696795 |
| P2093 | author name string | César Fernández | |
| | Luis A Salazar | |
| | Tomás Zambrano | |
| | Alejandro Cuevas | |
| | Alexy Rosales | |
| | Luis Ferrada | |
| P2860 | cites work | Genome-wide association of lipid-lowering response to statins in combined study populations | Q21142620 |
| | Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials | Q21261910 |
| | Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a) | Q24594382 |
| | Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans | Q24643492 |
| | Structural mechanism for statin inhibition of HMG-CoA reductase | Q27631717 |
| | Molecular basis for LDL receptor recognition by PCSK9 | Q27649779 |
| | The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor | Q28238069 |
| | High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) | Q28269517 |
| | Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study | Q28281870 |
| | Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins | Q29547856 |
| | SLCO1B1 variants and statin-induced myopathy--a genomewide study | Q29619028 |
| | LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice | Q30451602 |
| | SNP-SNP interactions dominate the genetic architecture of candidate genes associated with left ventricular mass in african-americans of the GENOA study | Q30478573 |
| | Molecular population genetics of PCSK9: a signature of recent positive selection. | Q33743727 |
| | Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans | Q34152058 |
| | Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population | Q34188099 |
| | Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia | Q34324688 |
| | Effects of genetic variants on lipid parameters and dyslipidemia in a Chinese population | Q34503417 |
| | Statin safety: a systematic review | Q34566154 |
| | The safety of statins in clinical practice | Q34636135 |
| | Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy | Q35127790 |
| | Traversing the conceptual divide between biological and statistical epistasis: systems biology and a more modern synthesis | Q36126271 |
| | Statins in the primary prevention of cardiovascular disease | Q38111961 |
| | Resistance and intolerance to statins | Q38226433 |
| | Beyond LDL cholesterol, a new role for PCSK9. | Q43016736 |
| | Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort | Q43209469 |
| | Short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia | Q44761374 |
| | Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9. | Q44811412 |
| | Variation in USF1 shows haplotype effects, gene : gene and gene : environment associations with glucose and lipid parameters in the European Atherosclerosis Research Study II. | Q44919442 |
| | Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia | Q45230897 |
| | Characterization of low-density lipoprotein cholesterol-lowering efficacy for atorvastatin in a population-based DNA biorepository | Q46332863 |
| | Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. | Q46885971 |
| | Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study | Q46975111 |
| | European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted | Q48527068 |
| P433 | issue | 4 | |
| P921 | main subject | Chile | Q298 |
| P304 | page(s) | 292-297 | |
| P577 | publication date | 2015-09-26 | |
| P1433 | published in | Basic and Clinical Pharmacology and Toxicology | Q15724438 |
| P1476 | title | HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals | |
| P478 | volume | 118 | |